Investors / United States / Rose Ventures
Rose Ventures
Investor · Falmouth, MA, United States · North America
Rose Ventures works with early-stage companies developing life science products and services, offering financing and advisory support alongside a network of life scientists and industry contacts. As of January 2026 it is part of Miles Pond Press, LLC, is fully allocated with no plans for future fundraising or investing, and continues to offer strategic advisory services to select clients.
Invests inHealthcare & Biotech
In its own wordslife scienceshealthcaregenomicsdiagnosticsbiotechnology
Your fit with Rose Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsRose Ventures lists 11 checked portfolio companies on its own site. Its largest themes are Healthcare & Biotech (82%), Education (9%) and Real Estate & Construction (9%). 100% of its companies are based in United States. It invests most often alongside A-Level Capital, ARTIS and Axial.
No funding round on record names Rose Ventures yet, so the figures come from its portfolio page.
Round figures show recent activity, not Rose Ventures' whole history. Rounds on record name 0 companies; its own site lists 11. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 27th | 11 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 94th | 82% in its largest sector |
| Reach | 19th | 1 country |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 82% | 15% |
| Education | 9% | 7% |
| Real Estate & Construction | 9% | 3% |
Co-investor network
who it backs companies with, and who they back togetherCompare Rose Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Portfolio
11 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Affinity Biosensors provides rapid AST test results with its LifeScale product | Healthcare & Biotech | Portfolio page | ||
| CellChorus develops and applies a single-cell analysis technology to understand how individual cells move, activate, interact, kill and survive | Healthcare & Biotech | Portfolio page | ||
| Chiara Biosciences develops medicines to tackle previously undrugged or inadequately drugged diseases | Healthcare & Biotech | Portfolio page | ||
| The Council on Strategic Risks conducts research and analysis on emerging risks, including climate and security issues | EducationReal Estate & Construction | Portfolio page | ||
| Glyphic Biotechnologies is developing a high-throughput proteome sequencing technology | Healthcare & Biotech | Portfolio page | ||
| Invenra discovers, optimizes, and engineers novel monoclonal, bispecific, and trispecific antibodies for clients | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Nira Skin sells at-home skincare lasers and related skincare products. | Healthcare & Biotech | Portfolio page | ||
| SAGA Diagnostics develops and commercializes a blood-based test for early detection of molecular residual disease in cancer patients | Healthcare & Biotech | Portfolio page | ||
| Eurofins Transplant Genomics develops molecular diagnostic tests to improve organ transplant outcomes | Healthcare & Biotech | Portfolio page | ||
| Verda Bio unlocks the potential of cannabinoids through cutting-edge genetic and ingredient research | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- roseventures.net
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Companies checked
- 11
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Rose Ventures' profile as data
Pull Rose Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/roseventures.net
# also
GET /v1/firms/roseventures.net/portfolio
GET /v1/firms/roseventures.net/coinvestors
GET /v1/firms/roseventures.net/news